|
業務類別
|
Biotechnology |
|
業務概覽
|
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). |
| 公司地址
| 3 Forbes Road, Lexington, MA, USA, 02421 |
| 電話號碼
| +1 781 674-4400 |
| 傳真號碼
| +1 781 674-4200 |
| 公司網頁
| https://www.agenusbio.com |
| 員工數量
| 316 |
| Ms. Christine M. Klaskin |
Vice President, Finance |
美元 298.22K |
14/01/2026 |
| Dr. Garo H. Armen, PhD |
Chairman of the Board, Chief Executive Officer, Interim Chief Financial Officer and Principal Financial Officer |
美元 715.26K |
14/01/2026 |
| Mr. Austin Charette |
Principal Accounting Officer |
-- |
14/01/2026 |
| Mr. Steven J. O'Day |
Chief Medical Officer |
美元 594.88K |
30/04/2025 |
|
|
| Mr. Timothy R. Wright |
Lead Independent Director |
30/04/2025 |
| Dr. Garo H. Armen, PhD |
Chairman of the Board, Chief Executive Officer, Interim Chief Financial Officer and Principal Financial Officer |
14/01/2026 |
| Mr. Brian J. Corvese |
Independent Director |
30/04/2025 |
| Mr. Thomas L. Harrison |
Independent Director |
30/04/2025 |
| Ms. Susan F. Hirsch |
Independent Director |
30/04/2025 |
| Dr. Jennifer S. Buell, PhD |
Director |
30/04/2025 |
|
|
|
|
